

Health Library
October 10, 2025
Question on this topic? Get an instant answer from August.
Lorlatinib ni umuti uvura kanseri ugamije guhagarika poroteyine zihariye zifasha kanseri zimwe na zimwe zo mu muhogo gukura no gukwirakwira. Uyu muti wandikirwa na muganga ugwa mu cyiciro cyitwa ALK inhibitors, zikora zihagarika ibimenyetso bibwira selile za kanseri kwiyongera.
Niba wowe cyangwa umuntu witaho yarandikiwe lorlatinib, ni ibisanzwe rwose kugira ibibazo byerekeye uko ikora n'icyo wakwitega. Uyu muti ugaragaza iterambere rikomeye mu kuvura ubwoko bwihariye bwa kanseri yo mu muhogo, utanga icyizere n'imikorere myiza ku barwayi benshi.
Lorlatinib ni umuti uvura ugamije kuvura kanseri yo mu muhogo idafite selile nto (NSCLC) ifite impinduka zihariye za genetike. Ni icyo abaganga bita "umuti w'ukuri" kuko ugamije poroteyine zihariye ziboneka muri selile za kanseri zimwe na zimwe.
Uyu muti uza mu buryo bw'ibinini bifatirwa mu kanwa. Bitandukanye na chimiotherapie ya gakondo igira ingaruka ku selile nyinshi zitandukanye mu mubiri wawe, lorlatinib igamije by'umwihariko selile za kanseri zifite ALK cyangwa ROS1 gene rearrangements. Ubu buryo bugamije akenshi busobanura ingaruka nke ugereranyije n'imiti ivura kanseri yagutse.
Muganga wawe azategeka ibizamini bya genetike by'igifu cyawe kugirango yemeze niba lorlatinib ikwiriye ubwoko bwawe bwihariye bwa kanseri. Ibi bizamini bifasha kumenya neza ko wakira ubuvuzi bwiza ku miterere yawe yihariye.
Lorlatinib ivura kanseri yo mu muhogo idafite selile nto yateye imbere yageze mu bindi bice by'umubiri. By'umwihariko, ikoreshwa iyo selile zawe za kanseri zifite impinduka mu gene yitwa ALK (anaplastic lymphoma kinase) cyangwa ROS1.
Uyu muti akenshi wandikwa iyo izindi miti yitwa ALK inhibitors itagikora neza. Ni ingenzi cyane kuko ishobora kwinjira mu bwonko, bigatuma ikora ku kanseri yageze mu bwonko. Abantu benshi babona ibi bishimishije cyane kuko kanseri yo mu bwonko ishobora kuba ikibazo gikomeye.
Umuvuzi wawe w’indwara z’umubiri ashobora no kugusaba gukoresha lorlatinib nk’umuti wa mbere niba ufite kanseri y’ibihaha ya ALK-positive iherutse kuvumburwa. Icyemezo gishingira ku bintu bitandukanye birimo ubuzima bwawe muri rusange, uko kanseri yawe yateye, n'uko ubuzima bwawe bwite buteye.
Lorlatinib ikora ibuza poroteyine zihariye zikenewe n'uturemangingo twa kanseri kugira ngo dukure kandi tubashe kubaho. Tekereza kuri izi poroteyine nk'ibishushanyo bibwira uturemangingo twa kanseri kwiyongera no gukwirakwira mu mubiri wawe.
Iyo ufata lorlatinib, yifatanya n'ibi bishushanyo bya poroteyine ikabizimya. Iki gikorwa gihagarika uturemangingo twa kanseri guhabwa ibimenyetso bakeneye kugira ngo bikure kandi bigabanuke. Bityo, uturemangingo twa kanseri akenshi turapfa cyangwa tukareka gukwirakwira mu bice bishya by'umubiri wawe.
Uyu muti ufatwa nk'ubuvuzi bukomeye kandi bwiza bugamije. Ni ingenzi cyane kuko ishobora kugera ku turemangingo twa kanseri mu bwonko, ibyo imiti myinshi ya kanseri idashobora gukora neza. Ibi bituma iba ingenzi cyane mu kuvura kanseri y’ibihaha yageze mu bwonko.
Fata lorlatinib nk'uko umuganga wawe abikwandikira, akenshi rimwe ku munsi hamwe n'ibiryo cyangwa nta biryo. Urashobora kuyifata n'ikirahure cy'amazi igihe icyo ari cyo cyose ku munsi, ariko gerageza kuyifata ku gihe kimwe buri munsi kugira ngo bikugiremo urwibutso.
Mimina ibinini byose utabinyanyaguye, utamena cyangwa ngo ubimene. Niba ugira ikibazo cyo kumira ibinini, ganira n'ikipe yawe y'ubuzima ku bijyanye n'uburyo bushobora gufasha. Bashobora kugira ibitekerezo byo koroshya gufata umuti wawe.
Ntugomba gufata lorlatinib hamwe n'ibiryo byihariye, ariko kugira imirire myiza mugihe uvurwa kanseri ni ingenzi. Abantu bamwe basanga kubifata hamwe n'akantu gato kabafasha kwirinda kubabara munda, nubwo ibyo bitabaye ngombwa.
Irinde imbuto za pome n'umutobe wazo mugihe ufata lorlatinib, kuko ibyo bishobora kongera umubare w'imiti mu maraso yawe. Muganga wawe azaguha urutonde rwuzuye rw'ibiryo n'imiti byo kwirinda.
Ubusanzwe uzakomeza gufata lorlatinib igihe cyose ikora neza kandi uyihanganira neza. Ibi bishobora kumara amezi cyangwa imyaka, bitewe n'uko kanseri yawe yitabira ubuvuzi.
Muganga wawe azakurikiza iterambere ryawe binyuze mu masozi asanzwe n'ibizamini by'amaraso. Ibi bizamini bifasha kumenya niba umuti urimo kugenzura kanseri yawe kandi niba urimo guhura n'ingaruka zose ziteye impungenge. Dushingiye kuri ibi bisubizo, gahunda yawe y'ubuvuzi irashobora guhindurwa.
Ntuzigere uhagarika gufata lorlatinib utabanje kubiganiraho na muganga wawe w'inzobere mu bya kanseri. N'iyo wumva umeze neza, umuti urashobora kuba ugikora kugirango ugenzure selile za kanseri utabasha kumva cyangwa kubona. Itsinda ryawe ry'ubuvuzi rizagufasha kumenya igihe n'uburyo bwo guhagarika ubuvuzi neza niba icyo gihe kigeze.
Kimwe n'imiti yose, lorlatinib irashobora gutera ingaruka, nubwo atari buri wese uzihura nazo. Abantu benshi bafata uyu muti neza, kandi ingaruka akenshi zirashobora gucungwa neza hamwe n'ubufasha bukwiye no gukurikiranwa.
Kumenya icyo witegura bishobora kugufasha kumva witeguye kandi ufite icyizere kubyerekeye ubuvuzi bwawe. Reka turebe ingaruka zisanzwe ushobora guhura nazo:
Inyinshi muri izi ngaruka ziba zoroheje kugeza ku gipimo cyo hagati kandi zishobora guhangana nazo neza. Itsinda ryawe rishinzwe ubuzima rizakugenzura neza kandi rigutange uburyo bwo kugufasha kumva umeze neza uko bishoboka kose mugihe cy'imiti.
Nubwo bidakunze kubaho, abantu bamwe bashobora guhura n'ingaruka zikomeye zisaba ubufasha bwihuse bw'abaganga. Izi ngaruka zitabaho ariko zikaba zikomeye zirimo:
Vugana n'itsinda ryawe rishinzwe ubuzima ako kanya niba uhuye n'ikimenyetso icyo aricyo cyose gikomeye cyangwa giteye impungenge. Bariho kugushyigikira kandi bakunze gutanga ibisubizo byo kugufasha gukomeza imiti neza.
Lorlatinib ntabwo ikwiriye kuri buri wese, kandi muganga wawe azasuzuma neza amateka yawe mbere yo kuyandika. Iri suzuma ryitondewe rifasha kumenya niba umuti ufite umutekano kandi ukwiriye kubera imiterere yawe yihariye.
Ntabwo ukwiriye gufata lorlatinib niba ufite allergie kuri yo cyangwa kuri kimwe mu bigize. Muganga wawe azaganira nawe kuri allergie izwi mbere yo gutangira imiti. Abantu bafite ibibazo bimwe na bimwe byari bisanzwe bakeneye kugenzurwa byihariye cyangwa imiti isimbura.
Ibintu byinshi bishobora kugira ingaruka niba lorlatinib ikwiriye kuri wowe:
Niba utwite cyangwa ushobora gutwita, ni ngombwa ko ubiganiraho n'umuganga wawe ako kanya. Lorlatinib ishobora gukomeretsa umwana utaravuka, bityo gukoresha uburyo bwo kuboneza urubyaro neza ni ngombwa mugihe cy'ubuvuzi no mu gihe runaka nyuma yo guhagarika imiti.
Itsinda ry'abaganga bazakorana nawe kugirango bamenye niba lorlatinib ariwo muti mwiza ukurikije uko ubuzima bwawe buhagaze n'amateka yawe y'ubuvuzi.
Lorlatinib igurishwa ku izina ry'ubucuruzi rya Lorbrena. Iri ni ryo zina uzabona ku icupa ry'umuti wawe no ku ipaki y'umuti.
Lorbrena ikorwa na Pfizer kandi iboneka gusa hamwe na resept yo kwa muganga wawe w'indwara z'umwijima. Farumasi yawe ishobora gukoresha izina ryombi mugihe bavuga ku miti yawe, bityo ni byiza kumenya izina rusange (lorlatinib) n'izina ry'ubucuruzi (Lorbrena).
Mugihe ufata umuti wawe cyangwa uvugana n'abaganga, urashobora kwita kuri izina ryombi. Amazina yombi yerekeza ku muti umwe ufite ikintu kimwe gikora.
Izindi nzitizi nyinshi za ALK zirahari niba lorlatinib atariwo muti mwiza kuri wowe. Muganga wawe w'indwara z'umwijima azatekereza ibintu bitandukanye muguhitamo umuti ukwiye kubera uko ubuzima bwawe buhagaze.
Izindi nzitizi za ALK zirimo alectinib (Alecensa), ceritinib (Zykadia), crizotinib (Xalkori), na brigatinib (Alunbrig). Buri muti muri uyu ukora kimwe muguhagarika poroteyine za ALK, ariko bafite ingaruka zitandukanye kandi zikora neza kurwanya ubwoko butandukanye bwa ALK.
Uburyo bwo guhitamo umuti wa ALK biterwa n'ibintu bitandukanye birimo niba warigeze guhabwa uwo muti wa ALK mbere, ubwoko bwihariye bwa ALK mutation ufite, niba kanseri yawe yaraguye mu bwonko. Muganga wawe azaganira nawe kuri izo nzira niba lorlatinib itakwemerera cyangwa igihe itagikora neza.
Byombi, lorlatinib na alectinib ni imiti ya ALK ikora neza, ariko buri imwe ifite ibyiza byayo bwite. Guhitamo "neza" biterwa n'imiterere yawe bwite, harimo ubwoko bwihariye bwa kanseri yawe n'amateka y'imiti wahawe.
Lorlatinib akenshi ikora neza kurwanya zimwe muri ALK mutations zanze gukora ku yindi miti ya ALK. Ikora neza cyane kandi mu kugera ku turemangingo twa kanseri mu bwonko, ibyo bikaba bifitiye akamaro gakomeye mu kuvura kanseri yaguye mu bwonko.
Ku rundi ruhande, alectinib ishobora gutera ingaruka nke ku mitekerereze kandi akenshi ikoreshwa nk'umuti wa mbere ku bantu basanzwemo kanseri y'ibihaha ya ALK-positive. Ifite kandi umutekano wemejwe kandi akenshi irihanganirwa neza.
Umuhanga wawe mu by'ubuvuzi azatekereza ku bintu nk'amateka yawe y'imiti wahawe, uko kanseri yawe yateye, n'ubuzima bwawe muri rusange mu gihe cyo guhitamo hagati y'iyo miti. Intego ni uguhitamo uburyo bwo kuvura buguha amahirwe meza yo kugenzura kanseri yawe mu gihe ukomeza ubuzima bwawe bwiza.
Lorlatinib ishobora kugira ingaruka ku mutima, bityo abantu bafite indwara z'umutima basanzwe bakeneye gukurikiranwa neza. Muganga wawe azasuzuma ubuzima bw'umutima wawe mbere yo gutangira kuvurwa kandi ashobora gutegeka ibizamini by'umutima nka EKG.
Niba ufite indwara y'umutima, ibyo ntibisobanura ko udashobora gufata lorlatinib, ariko uzakenera gukurikiranwa kenshi. Muganga wawe w'umutima n'uw'ibinyabuzima bazakorana kugira ngo barebe ko imiti yawe ifashwe neza uko bishoboka kose. Bashobora guhindura urugero rwawe cyangwa bagashyiraho gukurikiranwa k'umutima bikomeye mugihe uvurwa.
Niba ufata lorlatinib nyinshi bitunguranye kuruta uko byategetswe, vugana na muganga wawe cyangwa ikigo gishinzwe kurwanya ubumara ako kanya. Ntukegere ngo urebe niba wumva ibimenyetso, kuko gufashwa vuba ni ingenzi.
Bika urupapuro rw'imiti yawe hamwe nawe mugihe uhamagara, kuko abaganga bazakenera kumenya neza imiti yose yinyongera wafashe. Mugihe utegereje ubuyobozi, ntukongere gufata imiti yindi kandi wikurikirane niba hari ibimenyetso bidasanzwe nk'isuka ikabije, isereri, cyangwa urujijo.
Niba wirengagije urugero kandi hashize amasaha atarenze 20 kuva igihe cyari gisanzwe, fata urugero wirengagije ako kanya wibukira. Niba hashize amasaha arenga 20, reka urugero wirengagije maze ufate urugero rwawe rukurikira mugihe gisanzwe.
Ntuzigere ufata urugero rwa kabiri icyarimwe kugira ngo usimbure urugero wirengagije, kuko ibi bishobora kongera ibyago byo kugira ingaruka ziterwa n'imiti. Niba ukunda kwibagirwa urugero, vugana n'ikipe yawe y'ubuvuzi kubijyanye n'uburyo bwo kugufasha kwibuka, nko gushyiraho alarme kuri terefone cyangwa gukoresha umuteguro w'imiti.
Ugomba guhagarika gufata lorlatinib gusa mugihe muganga wawe akugiriye inama yo kubikora. Iyi myanzuro isanzwe ishingiye ku buryo imiti igenzura kanseri yawe neza niba urimo kugira ingaruka ziterwa n'imiti zishobora gucungwa.
Muganga wawe azakoresha isesengura risanzwe n'ibizamini by'amaraso kugira ngo akurikirane iterambere ryawe. Niba kanseri itangiye kongera gukura cyangwa niba ugize ingaruka zikomeye ziterwa n'imiti zitashobora gucungwa, muganga wawe ashobora kugusaba guhagarika lorlatinib no kugerageza uburyo bwo kuvura butandukanye.
Ni byiza kugabanya kunywa inzoga mu gihe ukoresha lorlatinib, kuko byombi bishobora kugira ingaruka ku mwijima wawe n'imitsi yawe. Inzoga ishobora gutuma ibimenyetso bimwe na bimwe byiyongera nk'izunguruka, urujijo, cyangwa impinduka z'amarangamutima.
Niba uhisemo kunywa inzoga rimwe na rimwe, bikore mu rugero kandi witondere uko wumva. Ganira na muganga wawe ku bijyanye n'ibibereye umwanya wawe wihariye, kuko bazi amateka yawe yose y'ubuvuzi kandi bashobora gutanga ubujyanama bwihariye.
6Mpeople
Get clear medical guidance
on symptoms, medications, and lab reports.